Switch theme
Sign up to access all valuation multiples
Humanwell Healthcare (Group) Co Ltd is a China-based integrated healthcare solution provider. Being a pharmaceutical company, it provides medicinal products including fertility-regulating drugs, Uygur medicine, traditional Chinese medicine, medical devices, over-the-counter medicines, anti-infection drugs, herbal medicines, and biological products. The organization has a business presence in China and other international countries.
1993
3.7K+
LTM Revenue $3.6B
LTM EBITDA $604M
$5.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Humanwell Healthcare has a last 12-month revenue (LTM) of $3.6B and a last 12-month EBITDA of $604M.
In the most recent fiscal year, Humanwell Healthcare achieved revenue of $3.5B and an EBITDA of $527M.
Humanwell Healthcare expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Humanwell Healthcare valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.6B | XXX | $3.5B | XXX | XXX | XXX |
| Gross Profit | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| Gross Margin | 45% | XXX | 45% | XXX | XXX | XXX |
| EBITDA | $604M | XXX | $527M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 15% | XXX | XXX | XXX |
| EBIT | $414M | XXX | $459M | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $236M | XXX | $185M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $614M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Humanwell Healthcare's stock price is CNY 22 (or $3).
Humanwell Healthcare has current market cap of CNY 36.2B (or $5.0B), and EV of CNY 41.2B (or $5.7B).
See Humanwell Healthcare trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.7B | $5.0B | XXX | XXX | XXX | XXX | $0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Humanwell Healthcare has market cap of $5.0B and EV of $5.7B.
Humanwell Healthcare's trades at 1.6x EV/Revenue multiple, and 10.8x EV/EBITDA.
Equity research analysts estimate Humanwell Healthcare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Humanwell Healthcare has a P/E ratio of 21.3x.
See valuation multiples for Humanwell Healthcare and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.0B | XXX | $5.0B | XXX | XXX | XXX |
| EV (current) | $5.7B | XXX | $5.7B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | 9.5x | XXX | 10.8x | XXX | XXX | XXX |
| EV/EBIT | 13.8x | XXX | 12.5x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.3x | XXX | 27.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 36.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHumanwell Healthcare's last 12 month revenue growth is 7%
Humanwell Healthcare's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.3M for the same period.
Humanwell Healthcare's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Humanwell Healthcare's rule of X is 33% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Humanwell Healthcare and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | 25% | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Humanwell Healthcare acquired XXX companies to date.
Last acquisition by Humanwell Healthcare was XXXXXXXX, XXXXX XXXXX XXXXXX . Humanwell Healthcare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Humanwell Healthcare founded? | Humanwell Healthcare was founded in 1993. |
| Where is Humanwell Healthcare headquartered? | Humanwell Healthcare is headquartered in China. |
| How many employees does Humanwell Healthcare have? | As of today, Humanwell Healthcare has 3.7K+ employees. |
| Is Humanwell Healthcare publicy listed? | Yes, Humanwell Healthcare is a public company listed on SHG. |
| What is the stock symbol of Humanwell Healthcare? | Humanwell Healthcare trades under 600079 ticker. |
| When did Humanwell Healthcare go public? | Humanwell Healthcare went public in 1997. |
| Who are competitors of Humanwell Healthcare? | Similar companies to Humanwell Healthcare include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Humanwell Healthcare? | Humanwell Healthcare's current market cap is $5.0B |
| What is the current revenue of Humanwell Healthcare? | Humanwell Healthcare's last 12 months revenue is $3.6B. |
| What is the current revenue growth of Humanwell Healthcare? | Humanwell Healthcare revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Humanwell Healthcare? | Current revenue multiple of Humanwell Healthcare is 1.6x. |
| Is Humanwell Healthcare profitable? | Yes, Humanwell Healthcare is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Humanwell Healthcare? | Humanwell Healthcare's last 12 months EBITDA is $604M. |
| What is Humanwell Healthcare's EBITDA margin? | Humanwell Healthcare's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Humanwell Healthcare? | Current EBITDA multiple of Humanwell Healthcare is 9.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
